JINHUA, China, Sept. 05, 2017 -- Kandi Technologies Group, Inc. (the "Company" or "Kandi") (NASDAQ GS:KNDI), today announced that Kandi Electric Vehicles Group Co., Ltd. (the "JV Company”) sold 3,213 units of electric vehicle (“EV”) products in August.
Mr. Hu Xiaoming, Chairman and Chief Executive Officer of Kandi, commented, “Our business was heavily impacted last year due to the confusion surrounding the reusable battery exchange model. We have been working diligently to resume the normal production gradually. We believe that we will regain our leading market position in the EV industry by the year end.”
About Kandi Technologies Group, Inc.
Kandi Technologies Group, Inc. (KNDI), headquartered in Jinhua, Zhejiang Province, is engaged in the research and development, manufacturing and sales of various vehicle products. Kandi has established itself as one of China's leading manufacturers of pure electric vehicle ("EV") products (through its joint venture), EV parts and off-road vehicles. Kandi conducts its primary business operations through its wholly-owned subsidiary, Zhejiang Kandi Vehicles Co., Ltd. (“Kandi Vehicles”), and the partially and wholly-owned subsidiaries of Kandi Vehicles.
More information can be viewed at the Company's corporate website at http://en.kandivehicle.com. The Company routinely posts important information on its website.
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Follow us on Twitter: @ Kandi_Group
Company Contact: Ms. Kewa Luo Kandi Technologies Group, Inc. Phone: 1-212-551-3610 Email: [email protected]


Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Italy Fines Apple €98.6 Million Over App Store Dominance
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 



